COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01400893
Recruitment Status : Terminated
First Posted : July 25, 2011
Results First Posted : August 29, 2017
Last Update Posted : September 27, 2017
Information provided by (Responsible Party):
CytoPherx, Inc

Brief Summary:
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Device: SCD Phase 2

Detailed Description:
Acute kidney injury is a condition where the kidneys are not capable of producing adequate urine. Therefore, another way to remove waste from the body is needed to hopefully allow time for the kidneys to heal. One method of removing waste from the body is called Continuous Renal Replacement Therapy (CRRT) or variations of that therapy. This study will evaluate the safety of the device while it is connected to the CRRT tubing for up to 7 days. Patients will be followed up until day 60 following the treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 134 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Study Start Date : August 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CRRT + SCD
Patients with a diagnosis of AKI requires CRRT will be randomized
Device: SCD
The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.

No Intervention: CRRT alone
Patients with a diagnosis of AKI requires CRRT will be randomized

Primary Outcome Measures :
  1. The Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization. [ Time Frame: Day 60 following treatment initiation ]

    All cause mortality through day 60 post-randomization.

    The outcome data reported here describe the mortality at Day 60 (primary endpoint) of the treated subjects which received the recommended ionized calcium (riCa) for ≥ 90% of treatment time.

Secondary Outcome Measures :
  1. Renal Replacement Therapy Dependency at Day 60. [ Time Frame: Day 60 following treatment initiation ]
    RRT dependency at day 60 is defined as patient not receiving any form of intermittent or continuous renal replacement therapy at 60 days post enrollment in the study with no plans for additional intermittent or continuous renal replacement therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. A patient, or legal representative, has signed a written informed consent form.
  2. Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).
  3. Age 18 to 80 years.
  4. Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
  5. Must be receiving and tolerating CRRT therapy for a minimum of 4 hours, but not longer than 24.
  6. Expected to remain in the ICU for at least 96 hours after evaluation for enrollment.
  7. A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is defined as Acute Kidney Injury occurring in a setting of acute ischemic or nephrotoxic injury with oliguria (average <20 mL/hr) for >6-12 hours or: an increase in serum creatinine ≥2 mg/dL (≥1.5 mg/dL in females) over a period of ≤4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies are excluded on clinical or other diagnostic grounds.)
  8. Presence of at least one non-renal organ failure or present sepsis as defined in Appendix C.
  9. All patients must be able to tolerate regional citrate anticoagulation.

Exclusion Criteria:

  1. Irreversible brain damage based on available historical and clinical information.
  2. Presence of any organ transplant at any time.
  3. Acute or chronic use of circulatory support device such as LVADs, RVADs, BIVADs, ECMO.
  4. Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury.
  5. AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity.
  6. Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy.
  7. Chronic immunosuppression (e.g., HIV/AIDS, chronic glucocorticoid therapy >20 mg/day prednisone equivalent on a chronic basis). The acute use of glucocorticoids is permissible.
  8. Severe liver failure as documented by a Child-Pugh Liver Failure Score >12 (see Appendix F).
  9. Currently in Do Not Resuscitate (DNR) status or DNR status anticipated within the next 7 days.
  10. Currently in Comfort measures Only or Comfort Measures Only status anticipated within next 7 days.
  11. Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
  12. Patient not expected to survive 28 days because of an irreversible medical condition. (This is not restrictive to AKI, and may include situations such as the presence of irreversible brain damage, untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is regarded as futile by the PI.)
  13. Any medical condition that the Investigator thinks may interfere with the study objectives.
  14. Physician refusal.
  15. Patient is a prisoner.
  16. Dry weight of >150 kg.
  17. More than one hemodialysis treatment during this hospital admission or prior to transfer from an outside hospital.
  18. Platelet count <30,000/mm3 at time of screening.
  19. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are allowed to participate.
  20. Use of any other Investigational drug or device within the previous 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01400893

Show Show 26 study locations
Sponsors and Collaborators
CytoPherx, Inc
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: CytoPherx, Inc Identifier: NCT01400893    
Other Study ID Numbers: SCD-003
First Posted: July 25, 2011    Key Record Dates
Results First Posted: August 29, 2017
Last Update Posted: September 27, 2017
Last Verified: May 2017
Keywords provided by CytoPherx, Inc:
Acute Renal Failure
Acute kidney injury
Acute tubular necrosis
Continuous Renal Replacement Therapy
Severe sepsis
Selective cytopheretic device
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases